Tag Archives: biotechnology law

Allergan V. Sandoz – When Everything “Old” Is “New” Again

Posted on May 2, 2013 by Warren Woessner

On Tuesday, a divided panel of the Fed. Cir. found that Allergan’s claimed method of reducing the number of daily topical doses of brimonidine to treat glaucoma from 3 to 2 doses by administering a composition containing 0.2% brimonidine and … Continue reading →

Posted in Inherency | Tagged Allergan v Sandoz, biotechnology, biotechnology law, Federal Circuit, intellectual property, ip, Patent Law, patents, Warren Woessner | Leave a comment

Federal Court Affirms BPAI in Dawson v. Dawson and Bowman

Posted on March 27, 2013 by Warren Woessner

This is a guest post from Theresa Stadheim of Schwegman Lundberg & Woessner In Chandler Dawson v. Chandler Dawson and Lyle Bowman, Appeal Nos. 2012-1214,-1215,-1216, -1217 (Fed. Cir. March 25, 2013) (a copy can be found at the end of … Continue reading →

Posted in Inventorship | Tagged biotechnology, biotechnology law, biotechnology news, BPAI, Dawson v Dawson, Federal Circuit, intellectual property, ip, Patent Law, patents, theresa Stadheim, Warren Woessner | Leave a comment

In Re Hubbell

Posted on March 20, 2013 by Warren Woessner

Guest post by Theresa Stadheim of Schwegman Lundberg & Woessner) In In Re Jeffrey Hubbell, Jason Schense, Andreas Zisch, and Heike Hall, Appeal No. 2011-1547 (Fed. Cir. March 7, 2013) (a copy can be found at the end of this post), … Continue reading →

Posted in Double Patenting | Tagged biotechnology, biotechnology law, BPAI, Double Patenting, Federal Circuit, Hubbell, intellectual property, ip, Patent Law, patents, theresa Stadheim, Warren Woessner | Leave a comment

UK National Stem Cell Network Report – The Patent Watch Landscape

Posted on March 7, 2013 by Warren Woessner

If you have either a passing or passionate interest in stem cell patenting, this report is worth some of your time. (A link to the report can be found at the end of this post.) The report analyzes the stem … Continue reading →